Stocks · News reference

Evotec shares are trading lower after the company reported worse-than-expected Q2 financial results.

Aug 13, 2026, 2:44 PMBenzinga Newsdesk

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 13, 2026, 10:46 AMBenzinga Newsdesk
Evotec Q2 EPS $(0.15) Misses $(0.06) Estimate, Sales $166.802M Miss $212.370M Estimate
Evotec (NASDAQ:EVO) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.06) by 150 percent. This is a 15.38 percent decrease over losses of $(0.14) per share from the same
Read original at benzinga
EVO
BenzingaAug 13, 2026, 8:49 AMBenzinga Newsdesk
Evotec Affirms FY2026 Sales Guidance of $667.470M-$714.310M vs $673.750M Est
Evotec (NASDAQ:EVO) affirms FY2026 sales outlook from $667.470 million-$714.310 million to $667.470 million-$714.310 million vs $673.750 million estimate.
Read original at benzinga
EVO
BenzingaAug 6, 2026, 6:53 AMBenzinga Newsdesk
Odyssey Taps Evotec's AI-Driven Discovery Platform To Advance Autoimmune, Inflammatory Disease Programs
Collaboration combines Odyssey's disease biology expertise with Evotec's AI-enabled discovery platform, advanced screening capabilities and proprietary compound libraries to support advancement of Odyssey's
Read original at benzinga
EVO ODTX